Akero Therapeutics shares are trading higher after Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $65 to $70.
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley maintained an Overweight rating on Akero Therapeutics and raised its price target from $65 to $70, causing the shares to trade higher.
June 12, 2023 | 2:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akero Therapeutics' stock price is trading higher after Morgan Stanley maintained an Overweight rating and raised its price target from $65 to $70.
Morgan Stanley's maintained Overweight rating and increased price target for Akero Therapeutics directly impacts the stock price, as it signals the firm's positive outlook on the company. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100